Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Grace Therapeutics, Inc.GRCE · Entity 7266 | Director | September 17, 2026 | September 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Grace Therapeutics, Inc.
Report date September 17, 2026 · Filed September 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.13 · Expires 2036-09-16 | Direct | 12,200 |
Reported balance
After 2026-09-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-17 · Grant · Acquired 12,200 · Balance 12,200 F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 17, 2026 Filed Sep 21, 2026 20:13 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 12,200 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0001140361-26-037237 · form4.xml · derivative · entry 1 Kottayil George · CIK 0001895357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,200 Underlying: Common Stock · 12,200 shares Expires 2036-09-16 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 16:01 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001140361-26-000968 · form4.xml · derivative · entry 1 Kottayil George · CIK 0001895357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2036-01-08 F1 · derivative.exercise_date: 25% of this option vests on the date of grant and the remaining 75% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2026, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 17:21 UTC | Grace Therapeutics, Inc. GRCE · Entity 7266 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001140361-25-018698 · form4.xml · derivative · entry 1 Kottayil George · CIK 0001895357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2035-05-09 F1 · derivative.exercise_date: 50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments on the 30th day of each month until September 30, 2025, subject to the Reporting Person's continuous service as of each vesting date. Read SEC document |
| December 19, 2023 Filed Dec 20, 2023 16:08 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | GrantStock Options (Right to Buy) · Derivative | 22,500 | $0.00 Strike: $2.13 | $0.00 |
DisclosureSEC source: 0000950170-23-071883 · ownership.xml · derivative · entry 1 Kottayil George · CIK 0001895357 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,500 Underlying: Class A Common Shares · 22,500 shares Expires 2033-12-19 F1 · derivative.exercise_date: Stock options granted on 12/19/2023 under the Acasti Pharma Stock Option Plan, which 10,000 shares vest in equal monthly installments over a period of 12 months (provided that 3/12 of the options shall be deemed to have vested upon the date of grant), and 12,500 shares vest in equal quarterly installments over a period of 18 months (Provided that 1/6 of the options shall be deemed to have vested upon the date of grant). Read SEC document |
| June 22, 2022 Filed Jun 23, 2022 16:34 UTC | Grace Therapeutics, Inc. ACST · Entity 7266 | Grant06/22/2022 · Derivative | 50,000 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001171843-22-004516 · ownership.xml · derivative · entry 1 Kottayil George · CIK 0001895357 · COO, US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Shares · 50,000 shares Expires 2032-06-22 F1 · derivative.exercise_price: Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant. F2 · derivative.exercise_date: Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.